Trials / Completed
CompletedNCT04605484
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- AlloVir · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Posoleucel (formerly known as ALVR105) cells | Infusion |
| BIOLOGICAL | Placebo (visually identical to Posoleucel) | Infusion |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2022-10-20
- Completion
- 2022-10-20
- First posted
- 2020-10-28
- Last updated
- 2024-05-16
- Results posted
- 2024-05-16
Locations
33 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04605484. Inclusion in this directory is not an endorsement.